Among patients with hypertension at high risk of cardiovascular disease, a program where patients measured their blood pressure and adjusted their antihypertensive medication accordingly resulted in lower systolic blood pressure at 12 months compared with patients who received usual care, according to a study in the Aug. 27 issue of JAMA.
Low-dose aspirin lowers the occurrence of new venous blood clots — and represents a reasonable treatment option for patients who are not candidates for long-term anticoagulant drugs, such as warfarin, according to a new study published in Monday's issue of Circulation.
Working-age adults with disabilities who do not get any aerobic physical activity are 50% more likely than their active peers to have a chronic disease — such as cancer, diabetes, stroke or heart disease — according to a Vital Signs report released earlier this week by the Centers for Disease Control and Prevention.
The Food and Drug Administration on Thursday approved Zontivity (vorapaxar) tablets, an anti-platelet agent that's designed to decrease the tendency of platelets to clump together to form a blood clot.
New guidelines for using statins to treat high cholesterol and prevent cardiovascular disease are projected to result in 12.8 million more U.S. adults taking the drugs, according to a research team led by Duke Medicine scientists.
New research published in the March issue of the American Journal of Medicine suggests that there is an association between a difference in interarm systolic blood pressure and a significant increased risk for future cardiovascular events, leading researchers to recommend expanded clinical use of interarm blood-pressure measurement.
Medication to treat high blood pressure in older patients appears to be associated with an increased risk for serious injury from falling, such as a hip fracture or head injury, especially in older patients who have been injured in previous falls, the JAMA Network Journals reported Monday.
Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.
Boehringer Ingelheim, a research-based, global pharmaceutical company, today announced a multi-year agreement with Brigham and Women's Hospital on a long-term study program to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation.
Recent data suggests that aspirin may be effective for reducing cancer deaths in addition to preventing heart attacks, raising the question whether the combined health benefits outweigh the risks of gastrointestinal bleeding and stroke for middle-aged men, researchers announced Wednesday.
The Food and Drug Administration last week approved the anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem. Eliquis is manufactured by Bristol-Myers Squibb, and marketed by BMS and Pfizer.
Researchers at the University of Gothenburg along with the Chalmers University of Technology earlier this month demonstrated that an altered gut microbiota in humans is associated with symptomatic atherosclerosis and stroke.
The National Community Pharmacists Association on Wednesday announced that it is participating in the "Team Up. Pressure Down." program to help hypertensive patients more effectively manage and control their high blood pressure — and ultimately prevent 1 million heart attacks and strokes by 2017.
People who suffer from sleep disturbances are at major risk for obesity, diabetes and coronary artery disease, according to new research from the Perelman School of Medicine at the University of Pennsylvania.